Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Non-interventional Study on the Effectiveness and Safety of Empagliflozin Compared With DPP-4 Inhibitors in Patients With Type 2 Diabetes in the United States

Trial Profile

Non-interventional Study on the Effectiveness and Safety of Empagliflozin Compared With DPP-4 Inhibitors in Patients With Type 2 Diabetes in the United States

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Nov 2018

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms EMPRISE
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 14 Nov 2018 Results of a first analysis from this study, presented at the 91st Annual Scientific Sessions of the American Heart Association
    • 05 Nov 2018 According to an Eli Lilly media release, this study is part of an academic collaboration between Brigham and Women's Hospital and Boehringer Ingelheim. Further results from this trial are expected in 2019.
    • 05 Nov 2018 According to an Eli Lilly media release, data from this trial will be presented at the American Heart Association (AHA) Scientific Sessions 2018 in Chicago.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top